108,000 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Purchased by State of Michigan Retirement System

State of Michigan Retirement System acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 108,000 shares of the company’s stock, valued at approximately $6,734,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC increased its stake in TransMedics Group by 33.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after buying an additional 219 shares during the last quarter. National Bank of Canada FI increased its stake in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after buying an additional 262 shares during the last quarter. Quarry LP increased its stake in TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares during the last quarter. Farther Finance Advisors LLC increased its stake in TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after buying an additional 316 shares during the last quarter. Finally, Park Avenue Securities LLC increased its stake in TransMedics Group by 3.8% in the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock valued at $548,000 after buying an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Canaccord Genuity Group decreased their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Oppenheimer reissued an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. Robert W. Baird reduced their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Down 3.2 %

TransMedics Group stock opened at $65.29 on Friday. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of 69.46 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a 50 day simple moving average of $68.18 and a 200 day simple moving average of $98.89.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.